ライフサイエンスコーパス: breast

1 tomography demonstrated reduced size of the breast and axillary disease, and no significant residual

2 d women's cancers, we describe the burden of breast and cervical cancer, with an emphasis on global a

3 rm is highly expressed in advanced stages of breast and cervical tumors.

4 the most established therapeutic targets in breast and gastric cancer but agents targeting Her2 have

5 as significantly associated with the risk of breast and gynecological cancers, and it may be utilized

6 in two murine tumor models, in primary human breast and lung cancer cells, and in deposited expressio

7 carboplatin are used primarily in germ cell, breast and lung malignancies, oxaliplatin is instead use

8 ex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of c

9 ers and is correlated with poorer outcome in breast and other cancers.

10 r risk from birth, as estimated by BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Car

11 ction of prognosis and treatment response in breast and ovarian cancers.

12 -38 different common and rarer cancers, with breast and prostate cancer as baseline categories for wo

13 ge in breast appearance [p=0.007 for partial-breast] and breast harder or firmer [p=0.002 for reduced

14 gnificantly lower adverse effects (change in breast appearance [p=0.007 for partial-breast] and breas

15 s, were significantly increased for invasive breast cancer (9 more cases [95% CI, 1 to 19]), probable

16 The primary tumors were breast cancer (92 patients, 426 scans), non-Hodgkin lymp

17 Examination of molecular signatures of breast cancer (based on complex gene expression patterns

18 Breast cancer (BC) has a higher incidence in young Leban

19 Adjuvant radiotherapy (RT) in breast cancer (BC) is often used to eradicate remaining

20 Triple-negative (TN) breast cancer (BC) shares histological characteristics w

21 types with lower SSTR expression, including breast cancer (BC).

22 st1 expression is associated with basal-like breast cancer (BLBC) with poor prognosis owing to its ro

23 Patients with breast cancer (BrCa) brain metastases (BrM) have limited

24 receptor tyrosine kinase 2 (ErbB2)-positive breast cancer (ErbB2(KI)), which exhibits aberrant beta-

25 Foxa1 expression is linked with luminal breast cancer (LBC) with good prognosis, whereas Twist1

26 During the same period, deaths after breast cancer (n = 134) were significantly reduced (40 d

27 Triple-negative breast cancer (TNBC) comprises approximately 20% of all

28 eceptor-negative (ER(-)) and triple-negative breast cancer (TNBC), nitric oxide synthase-2 (NOS2) and

29 ghly activated in basal-like triple-negative breast cancer (TNBC).

30 t cancer, 16.5% had average or lower risk of breast cancer according to the Breast Cancer Risk Assess

31 but we did see a 19% excess risk of invasive breast cancer among those with AF (adjusted hazard ratio

32 40-55 years) eligible for the contralateral breast cancer analysis, 426 were diagnosed with breast c

33 e range [IQR], 30-46 years) eligible for the breast cancer analysis, 5066 women (median age, 38 years

34 Here we adopt this powerful approach to breast cancer and analyse 515 cells from 11 patients.

35 I trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were ran

36 44 years who were diagnosed with early-stage breast cancer and received a CPM increased in many state

37 vant systemic therapy (NST) in patients with breast cancer and to outline a model of pathologic respo

38 treatment solutions to benefit patients with breast cancer at high risk of recurrence.

39 men diagnosed with unilateral stage I to III breast cancer between 1998 and 2012 within the Surveilla

40 me, sensitive electrochemical detection of a breast cancer biomarker microRNA (miRNA), mir-21 was ach

41 m), we demonstrated specific localization to breast cancer bone metastases in mice.

42 ual identification of presence and extent of breast cancer by a pathologist is critical for patient m

43 ondary cancers in women with newly diagnosed breast cancer by using histologic or imaging follow-up a

44 ollow-up (2004 to 2011), 2,407 first primary breast cancer cases were identified.

45 t strategies to prevent cancer metastasis in breast cancer cases.

46 ific demethylase KDM3A played a dual role in breast cancer cell invasion and apoptosis by demethylati

47 us to discriminate between normal and human breast cancer cell lines (fibrocystic and metastatic sta

48 fold more potent at inhibiting the growth of breast cancer cell lines (MCF7, MCF7/VP16, BT474, T47D,

49 rbon monoxide (CO) reduced GSH/GSSG in three breast cancer cell lines by inhibiting CBS.

50 To investigate this question, we developed breast cancer cell lines expressing an inducible, consti

51 defects by direct and indirect assays in 12 breast cancer cell lines to estimate the spontaneous occ

52 h GSK1016790A reduced viability of two basal breast cancer cell lines with pronounced endogenous over

53 1 in total RNA extracted from human lung and breast cancer cell lines, discriminating between the can

54 ells, also inhibit endothelial phenotypes of breast cancer cells adopted in response to a nutrient-de

55 Here, we first demonstrated that breast cancer cells and pancreatic adenocarcinoma cells

56 the human genome, are overexpressed in some breast cancer cells and tissues but without regard to ca

57 ine and reveal that enhancers transcribed in breast cancer cells direct critical gene regulatory netw

58 with DAC to reduce the viability of luminal breast cancer cells in in vitro assays.

59 ration and activated apoptosis in MDA-MB-231 breast cancer cells in vitro and in vivo.

60 ngeneic studies with orthotopically injected breast cancer cells in wild-type and RAGE-knockout C57BL

61 Accordingly, E+P treatment of breast cancer cells increased ER binding to the NEMO pro

62 estigate the unique transhesive profiles for breast cancer cells that are adapted to colonize differe

63 we demonstrate that treatment of human MCF-7 breast cancer cells with pro-inflammatory cytokines resu

64 Here, we characterize, in breast cancer cells, the molecular effects of a recently

65 Indeed, when CXCR7 was silenced in breast cancer cells, their metastatic ability was inhibi

66 S nanoparticles that target HER2 and CD44 in breast cancer cells, we demonstrate labeling of fixed ce

67 /HER2 in normal mammary epithelial cells and breast cancer cells.

68 promote invadopodial maturation in invasive breast cancer cells.

69 ted regulation of invasion and metastasis in breast cancer cells.

70 vitro and cell-based model of MMP-dependent breast cancer cellular invasiveness, this N-TIMP2 mutant

71 g disease regression in treatment-refractory breast cancer chest wall metastases but responses are sh

72 ence and disability pension among women with breast cancer compared with women without breast cancer.

73 Here, we analyzed human breast cancer data to identify transcriptional programs

74 h shorter patient delay and earlier stage at breast cancer diagnosis.

75 Women were followed until February 2015 or breast cancer diagnosis.

76 ists, and behavioral scientists to eliminate breast cancer disparities related to racial/ethnic ident

77 hly effective in inhibiting ERalpha-negative breast cancer due at least in part to epigenetic reactiv

78 h ovarian cancer, and 245 with contralateral breast cancer during follow-up.

79 Health Study (WCHS) in the African American Breast Cancer Epidemiology and Risk Consortium.

80 s between medications of interest and second breast cancer events was observed when surveillance was

81 Traditional treatments for breast cancer fail to address therapy-resistant cancer s

82 olling mammary stem cell (MaSC) activity and breast cancer formation remain poorly understood.

83 In six of the 52 patients, breast cancer had been diagnosed at an outside instituti

84 carcinogenic effects, but protection against breast cancer has not been established.

85 Evidence on everolimus in breast cancer has placed hyperglycemia among the most co

86 neoadjuvant chemotherapy (NAC) for operable breast cancer has raised questions about optimal local t

87 xC(-) activity in vivo and its potential for breast cancer imaging.

88 relation of T2D to incidence of ER- and ER+ breast cancer in data from the Black Women's Health Stud

89 ctive cohort study, we evaluated the risk of breast cancer in relation to indoor heating and cooking

90 optimized lead compound (38u) that represses breast cancer invasion and migration.

91 erior therapeutic efficacy.MEK inhibition in breast cancer is associated with increased tumour infilt

92 Breast cancer is the most common cancer among women and

93 d by nasopharyngeal carcinoma CNE2 cells and breast cancer MDA-MB-231 cells, where these tumor cells

94 regulation of kinesin-1 motor functions and breast cancer metastasis and suggest PLD2 as a potential

95 The majority of breast cancer models for drug discovery are based on ort

96 associations of vitamin D with lower risk of breast cancer morbidity and mortality.

97 In cell models of human breast cancer or in a cyclin D1-deficient model, we obse

98 Breast cancer originates from this epithelium, but the m

99 n analyzed gene expression profiles of human breast cancer patients and patient-derived xenograft (PD

100 In node-positive breast cancer patients treated with neoadjuvant chemothe

101 , representing novel therapeutic targets for breast cancer patients who smoke.

102 reliable prognostic biomarker in ER positive breast cancer patients, and predictive of preclinical se

103 ay significantly increase response rates for breast cancer patients, especially those with HER2 and E

104 static niche formation and poor prognosis in breast cancer patients.

105 d in cancers and signifies poor prognosis of breast cancer patients.

106 nd correlate with metastatic status in human breast cancer patients.

107 tween Src kinases, paxillin, and survival of breast cancer patients.

108 even independent data sets with totally 1079 breast cancer patients.

109 utation carriers leading to an international breast cancer prevention trial, and insights into the in

110 h centrally confirmed HER2-positive advanced breast cancer previously treated with both trastuzumab a

111 HD levels were independently associated with breast cancer prognostic characteristics and patient pro

112 ess response miRNA whose activity may define breast cancer progression and survival.

113 al relationships between Twist1 and Foxa1 in breast cancer progression are unknown.

114 tential benefits of vitamin D for preventing breast cancer recurrence and mortality, yet data from pr

115 -response elements and significantly induced breast cancer resistance protein (BCRP) gene transcripti

116 lower risk of breast cancer according to the Breast Cancer Risk Assessment Tool (Gail score).

117 graphic density (MD) is one of the strongest breast cancer risk factors.

118 ntal samples and extensive data on potential breast cancer risk factors.

119 according to genetic risk based on lifetime breast cancer risk from birth, as estimated by BOADICEA

120 en from 25 to 76 years of age with increased breast cancer risk who underwent CE spectral mammography

121 ndpoint was participation (ie, attendance at breast cancer screening) within 90 days of the date of t

122 A healthy control subjects from the Carolina Breast Cancer Study (CBCS) and the Women's Circle of Hea

123 ee patients were recruited from the Shanghai Breast Cancer Survival Study, a longitudinal study of pa

124 eight loss intervention for African American breast cancer survivors (AABCS) on weight, body composit

125 been identified and contribute to hereditary breast cancer syndromes.

126 generating PIP2, is positively expressed in breast cancer tissues, which correlates intimately with

127 related with beta-catenin and PKM2 levels in breast cancer tissues.

128 TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo

129 r who are at risk for receiving nonguideline breast cancer treatment, which probably contributes to p

130 l of targeting YAP-BCAR4-glycolysis axis for breast cancer treatment.

131 oller of Wnt/beta-catenin signaling-mediated breast cancer tumorigenesis, metastasis, and cancer stem

132 were used to identify females with invasive breast cancer undergoing planned mastectomy.

133 alculated pore size of a brain metastasis of breast cancer was approximately 10-fold smaller than gli

134 d States from 2009 to 2013, the incidence of breast cancer was the highest of any cancer and the deat

135 risk of receiving nonguideline treatment of breast cancer were assessed in multivariable logistic re

136 The pharmacokinetic parameters of breast cancer were calculated by using the Tofts model w

137 013, 235 women undergoing PM for Stage 0-III breast cancer were randomized to undergo either standard

138 led trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatmen

139 constitute a large subgroup of patients with breast cancer who are at risk for receiving nonguideline

140 Women with stages I to III breast cancer who received all or part of their treatmen

141 Conclusion Patients with breast cancer who were treated in community oncology cli

142 odels to investigate whether associations of breast cancer with body mass index (BMI; weight (kg)/hei

143 uce the expression of pro-apoptotic genes in breast cancer with mutant p53.

144 e available on the survival of patients with breast cancer with preexisting mental illness, and elder

145 ), A549 (lung adenocarcinoma) and MDA-MB-231(breast cancer).

146 ast cancer analysis, 426 were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with con

147 Although all had a biologic sister with breast cancer, 16.5% had average or lower risk of breast

148 iated relative risk for male than for female breast cancer, although absolute excess risks for males

149 e advances in the diagnosis and treatment of breast cancer, breast cancers still cause significant mo

150 Triple-negative breast cancer, compared with non-TNBC, likely arises fro

151 for 1 year, unless disease recurrence or new breast cancer, intolerable adverse events, or consent wi

152 eatment with chemotherapy and a diagnosis of breast cancer, non-Hodgkin lymphoma, or gynecologic canc

153 brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort a

154 Now, almost 90 years after its first use in breast cancer, technology developments in diagnostic ima

155 eptor-positive, HER2-negative, node-positive breast cancer, the MammaPrint assay may be used in patie

156 -based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs no scalp cool

157 orubicin (Cyclo/Dox), a common treatment for breast cancer, to female BALB/c mice near the beginning

158 In clinical specimens of breast cancer, TRIB1 levels correlated with expression o

159 regnancy 6 months or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women

160 es to immune escape in an aggressive form of breast cancer, with potential implications for a novel i

161 major advances in the treatment of advanced breast cancer, with several targeted therapies that enha

162 Tumor recurrence remains the main reason for breast cancer-associated mortality, and there are unmet

163 Tumor recurrence is the leading cause of breast cancer-related death.

164 Breast cancer-specific survival assessed by Kaplan-Meier

165 h probably contributes to poorer overall and breast cancer-specific survival.

166 patients with locally relapsed or metastatic breast cancer.

167 ome microRNAs (miRNAs) are known to suppress breast cancer.

168 hanism for the involvement of this region in breast cancer.

169 scular preventive therapy after diagnosis of breast cancer.

170 advanced adenomas), endometrial cancers, and breast cancer.

171 (2), respectively, and 82% had stage I or II breast cancer.

172 decision making in patients with unilateral breast cancer.

173 ohistochemically in patients with metastatic breast cancer.

174 several known histopathological subtypes of breast cancer.

175 ith brain metastases at time of diagnosis of breast cancer.

176 crine therapy resistance in OXPHOS-dependent breast cancer.

177 e whose heterozygous mutations predispose to breast cancer.

178 n age >/= 65 years who reported a history of breast cancer.

179 tic hormone receptor-positive, HER2-negative breast cancer.

180 s that are commonly used in the treatment of breast cancer.

181 ma but generally fail in brain metastases of breast cancer.

182 se orthotopic model of human triple-negative breast cancer.

183 th breast cancer compared with women without breast cancer.

184 suppressor BRCA2 predominantly predispose to breast cancer.

185 its potential risks on venous thrombosis and breast cancer.

186 lated to the pathogenesis of triple-negative breast cancer.

187 geted therapy in patients with HER2-positive breast cancer.

188 ctory, estrogen receptor-positive metastatic breast cancer.

189 one therapeutic efficacy in ERalpha-negative breast cancer.

190 tumour growth in a transgenic mouse model of breast cancer.

191 en-dependent diseases like endometriosis and breast cancer.

192 cyclines in patients with early TOP2A-normal breast cancer.

193 tumor progression in an aggressive model of breast cancer.

194 potential therapeutic target for metastatic breast cancer.

195 milar to that seen in patients with invasive breast cancer.

196 use they experience the highest incidence of breast cancer.

197 ion about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders.

198 by age and menopausal status in over 11,000 breast-cancer-free women aged 35-85 years, from 40 ethni

199 he high mortality rates associated with most breast cancers (BC).

200 Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-ap

201 Triple-negative breast cancers (TNBCs) are more common among African-anc

202 se Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for an

203 RF1 expression is increased in HER2-positive breast cancers and correlates with HER2-positive status

204 er (TNBC) comprises approximately 20% of all breast cancers and is the most aggressive mammary cancer

205 In a population in which most breast cancers are self-detected, previous clinical brea

206 arcinoma in situ (DCIS) lesions and invasive breast cancers as well as with increased mortality in pa

207 improve early diagnosis directly by finding breast cancers at earlier stages or indirectly by height

208 than 50% of estrogen receptor (ER)-positive breast cancers coexpress the progesterone receptor (PR),

209 The majority of breast cancers expresses the estrogen receptor (ER(+)) a

210 data set, was highly enriched in basal-like breast cancers in young individuals of African descent.

211 he diagnosis and treatment of breast cancer, breast cancers still cause significant mortality.

212 follow-up (mean = 6.4 years), 1,843 invasive breast cancers were diagnosed.

213 etween 0 (thyroid, ascites) and 8.48 months (breast cancers)-and were sometimes based on modeled data

214 In 13 breast cancers, 8 had a low binding (mean density, 844 +

215 differences shown for lung, colorectal, and breast cancers, respectively.

216 sts of passengers in cell lines and in human breast cancers.

217 ER2 has been reported in around 25% of human breast cancers.

218 rom 520 patients with metastatic prostate or breast cancers.

219 clinical outcome in estrogen receptor+ (ER+) breast cancers.

220 lation analysis of public databases of human breast carcinoma and IHC analysis of mice xenograft tumo

221 ocarcinoma, lung squamous cell carcinoma and breast carcinoma cancer cells.

222 ry human macrophages (MPhi) with human MCF-7 breast carcinoma cells, which caused cell death of cance

223 fect on constitutive ERK activity in HER2(+) breast carcinoma cells.

224 By identifying Nck as an important driver of breast carcinoma progression and metastasis, these resul

225 myeloid leukemia, but is also detectable in breast carcinoma where its contributions are unexplored.

226 emical inflammation (turpentine) and cancer (breast carcinoma).

227 Ms in different cancer models: 4T1 and MCF-7 breast carcinoma, B16F10 melanoma, WT-GBM glioma and MKN

228 hat CD44 might be a novel target of DACH1 in breast carcinoma.

229 ng as a prominent EVI1 effector mechanism in breast carcinoma.

230 sion exhibits strong correlations in primary breast carcinomas.

231 47D, ZR-75-1, SKBR3, MDA-MB-468) than normal breast cells (MCF-10A) or cell lines derived from other

232 -Tyr(3)-octreotide in cancers from prostate, breast, colon, kidney, thyroid, and lymphoid tissues as

233 02 for reduced-dose and p<0.0001 for partial-breast]) compared with whole-breast radiotherapy.

234 Of 1697 patients, breast conserving therapy was performed in 656 (39%), ma

235 with BC treated with radiotherapy (RT) after breast-conserving surgery.

236 When compared with breast-conserving therapy, we found no significant impro

237 Both tumor and normal breast contain high-abundance "enriched" sequences that

238 different pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC.

239 Here, we reveal that the breast epithelial clock is regulated by the mechano-chem

240 , but the molecular mechanisms that underlie breast epithelial hierarchy remain ill-defined.

241 Clinical breast examination may improve early diagnosis directly

242 cancers are self-detected, previous clinical breast examination was associated with shorter patient d

243 dies are predominantly maternally derived in breast-fed children.

244 ex, gestational age, birthweight, parity and breast feeding), maternal characteristics (mother's age

245 (P < .05) if mothers consumed peanuts while breast-feeding but delayed introducing peanuts to their

246 she experienced progressive painful pruritic breast fullness, skin dimpling, and skin discoloration o

247 duced-dose group and p=0.016 for the partial-breast group, compared with the whole-breast radiotherap

248 appearance [p=0.007 for partial-breast] and breast harder or firmer [p=0.002 for reduced-dose and p<

249 directly by heightening women's awareness of breast health concerns.

250 Material/A total of 100 patients with no breast lesions and a total of 100 patients with malignan

251 contour (SWATC) display for the diagnosis of breast lesions and to identify factors associated with t

252 s and a total of 100 patients with malignant breast lesions were included in the study.

253 quality of shear wave propagation (QSWP) in breast lesions.

254 fferential diagnosis of malignant and benign breast lesions.

255 t material-enhanced spectral mammography and breast magnetic resonance (MR) imaging in the detection

256 fy the diagnostic accuracy of intraoperative breast margin assessment (IMA) techniques against which

257 differentiation between malignant and benign breast masses, but it should be used in conjunction with

258 lone in differentiating benign and malignant breast masses.

259 nimal studies using mice carrying orthotopic breast MDA-MB-231 tumors showed that the cyclic peptide

260 was used to estimate the contribution of the breast milk and areolar skin microbiomes to the infant g

261 What lactating mothers eat flavors breast milk and, in turn, modifies their infants' accept

262 m infants who were fed solids in addition to breast milk at 4 mo postpartum achieved both standing [a

263 were associated with the proportion of daily breast milk intake in a dose-dependent manner, even afte

264 Breast milk is rich in PUFA, and it has been hypothesize

265 of n-3 and n-6 PUFA levels in colostrum and breast milk with allergic disease and lung function at a

266 n not to affect their total concentration in breast milk.

267 tivity in serial passage culture and in vivo breast morphogenesis relies on the preservation of a myo

268 growth in vivo using an orthotopic xenograft breast mouse model.

269 re included in the dynamic contrast-enhanced breast MR imaging protocol with a 1.5-T MR imaging syste

270 Breast MR imaging was performed before and after treatme

271 Methods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed t

272 (89.6%) with and 68 of 160 (42.5%) without a breast pCR had no evidence of residual nodal disease (P

273 surgery when image-guided biopsy indicates a breast pCR.

274 ated factors are affecting the likelihood of breast preservation.

275 Accelerated partial breast radiation treatment was completed in February 200

276 mber 2013, 9 years after accelerated partial breast radiation treatment, she experienced progressive

277 artial-breast group, compared with the whole-breast radiotherapy group).

278 be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test again

279 dverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achie

280 001 for partial-breast]) compared with whole-breast radiotherapy.

281 , 2015, among ambulatory patients undergoing breast reconstruction at an academic ambulatory care hos

282 rafting has proven to be a useful adjunct to breast reconstruction for the treatment of contour irreg

283 hospital variation for autologous free flap breast reconstruction is unknown.

284 The mean cost for autologous free flap breast reconstruction was $22677 (interquartile range, $

285 making is needed to support decisions about breast reconstruction.

286 ure, the fat-grafted cohort reported similar breast satisfaction (AMD, -0.68; 95% CI, -4.42 to 3.06;

287 njected subareolarly for localization of the breast SLN and isosulfan blue dye (5 mL) is injected in

288 del for studying oncogenic transformation in breast tissues.

289 onal digital mammography (DM) versus digital breast tomosynthesis (DBT) mammography.

290 increases interleukin (IL)-33 released from breast tumor cells, which is crucial for the induction o

291 in both murine xenograft and patient-derived breast tumor explant models.

292 onder phenomenon in an aggressive MCF10-CA1a breast tumor model.

293 uced the cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 1

294 REKA-Lipo-Dox) for the therapy of metastatic breast tumor.

295 Further, we showed that HNK inhibited breast tumorigenesis in mice in an LKB1-dependent manner

296 e in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodistribution

297 lified in 11% and/or overexpressed in 15% of breast tumors, and overexpression of MYST3 correlated wi

298 cohort of 43 ER+ HER2- and ER- HER2- primary breast tumors, confirming many of the exon events identi

299 scence in-situ hybridisation of two cores of breast tumour tissue in a microarray, done in a central

300 resented with multifocal cancer in the right breast, with lesions at 1:00 and 4:00, the largest measu